Please login to the form below

Not currently logged in
Email:
Password:

Servier defends Perindopil overcharging claim

Servier refutes claims made by the UK's Department of Health the company is overcharging for high blood pressure and heart disease drug Perindopil

Servier is contesting legal action by the UK's Department of Health (DH), which claims the French drug manufacturer charged £220m too much for its high blood pressure and heart disease drug perindopril.

A report in the UK paper, the Daily Mail, alleges that Health Secretary Andrew Lansley has accused Servier of forcing doctors to pay for expensive versions of the pills when generic ones were available.

Lansley also alleges that the company paid millions of pounds to rivals not to make generic versions, after its patent ran out in 2001, according to the report.

Lansley is leading the action at the High Court with ten strategic health authorities and 157 primary care trusts to reclaim money the NHS was overcharged between 2001 and 2007.

A spokeswoman for Servier said: "We are contesting the claim and we are confident that the right outcome will be reached."

Meanwhile a spokeswoman for the DH told PMLiVE that the department could not comment on ongoing proceedings.

Earlier this year Lansley took legal action against Reckitt Benckiser, claiming nearly £90m for overcharging for heartburn drugs.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics